“We recommend doing the spot cautery,” says Andrew Higgins, MD.
In this video, Andrew Higgins, MD, discusses how the combination of Aquablation therapy and electrocautery has already shown promise and will be researched further to continue to advance BPH treatment. “Prostate Aquablation: 2 years of perioperative outcomes,” presented recently at the 2021 American Urological Association annual meeting. Higgins is a urology resident at Einstein Healthcare Network, Philadelphia, Pennsylvania.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.